About: Review article: genetic factors that modify the outcome of viral hepatitis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Review article: genetic factors that modify the outcome of viral hepatitis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Review article: genetic factors that modify the outcome of viral hepatitis
Creator	Hofer, H Beinhardt, S Ferenci, Ferenci, P Rutter, K Scherzer, T St€, A
source	Medline; PMC
abstract	BACKGROUND: Genetic factors can play an important role for treatment response and disease progression in chronic viral hepatitis. AIM: To review the influence of host genetic factors on the clinical course as well as on treatment response in patients with viral hepatitis. METHODS: Review of the literature. RESULTS: A landmark genome‐wide association study (GWAS) identified polymorphisms in the IL28B gene on chromosome 19 (19q13.13) associated with response to therapy with pegylated interferon‐α (PEG‐IFN) and ribavirin (RBV) and spontaneous viral clearance in acute hepatitis C. Furthermore, IL28B genotype is associated with changes of lipid metabolism and insulin resistance. A further GWAS demonstrated that ITPA genetic variants protect HCV genotype 1 patients from RBV‐induced anaemia. Another polymorphism in the patatin‐like phospholipase domain containing 3 (PNPLA3) is associated with hepatic steatosis. Difficult‐to‐treat hepatitis C patients homozygous for GG had an up to five‐fold lower chance of viral clearance on PEG/RBV than non‐GG patients. In chronic hepatitis B patients treated with PEG‐IFN several retrospective analyses of IL28B rs12980275 and rs12979860 genotypes yielded conflicting results which can be explained by the heterogeneity between the study populations. Some variants of the HLA‐DP locus (HLA‐DPA1 A allele and HLA‐DPB1) protect against progression of chronic hepatitis B infection. CONCLUSIONS: The determination of IL28B polymorphisms may be useful to individualise treatment options when using PEG/RBV based therapies for chronic hepatitis C infection. In contrast, so far identified genetic factors play only a minor role in chronic hepatitis B infection.
has issue date	2014-03-24(xsd:dateTime)
bibo:doi	10.1111/apt.12717
bibo:pmid	24654629
has license	no-cc
sha1sum (hex)	3a8b9391d5ea0d974fe1ed87c854863dd0ee41f4
schema:url	https://doi.org/10.1111/apt.12717
resource representing a document's title	Review article: genetic factors that modify the outcome of viral hepatitis
has PubMed Central identifier	PMC7159786
has PubMed identifier	24654629
schema:publication	Aliment Pharmacol Ther
resource representing a document's body	covid:3a8b9391d5ea0d974fe1ed87c854863dd0ee41f4#body_text
is schema:about of	named entity 'hazard ratio' named entity 'HBeAg' named entity 'genotype' named entity 'SVR' named entity 'fibrogenesis' named entity 'prospective study' named entity 'IL28B' named entity 'protease inhibitors' named entity 'infection' named entity 'Basel' named entity 'protease inhibitor' named entity 'NS5B polymerase' named entity 'cross-sectional analysis' named entity 'HBV' named entity 'chronic hepatitis' named entity 'IL28B' named entity 'patient cohorts' named entity 'HBsAg' named entity 'IL28B' named entity 'IL28B' named entity 'IL28B' named entity 'tapasin' named entity 'IFN-a' named entity 'anaemia' named entity 'frameshift' named entity 'HBeAg' named entity 'IL28B' named entity 'methionine' named entity 'seroconversion' named entity 'polymorphism' named entity 'hepatic decompensation' named entity 'long-term' named entity 'genotype' named entity 'genetic factors' named entity 'HBeAg' named entity 'HLA-DPB1' named entity 'Sf9' named entity 'hepatocellular carcinoma' named entity 'genotype' named entity 'polymorphisms' named entity 'Odds ratio' named entity 'polymorphisms' named entity 'genotype' named entity 'clinical outcome' named entity 'HCV' named entity 'erythropoietin' named entity 'liver cirrhosis' named entity 'HBV' named entity 'liver disease' named entity 'B-lymphocytes' named entity 'boceprevir' named entity 'Janssen Therapeutics' named entity 'polymorphisms' named entity 'peripheral blood mononuclear cells' named entity 'liver fat' named entity 'IL28B' named entity 'HBV' named entity 'IFN' named entity 'chromosome 20' named entity 'pegylated interferon' named entity 'NS5B' named entity 'fibrosis' named entity 'dendritic cells' named entity 'deleobuvir' named entity 'blood transfusions' named entity 'anti-viral' named entity 'interferon' named entity 'TVR' named entity 'virions' named entity 'acyl groups' named entity '9.08' named entity 'MSD' named entity 'genotypes' named entity 'CHB' named entity 'hepatic steatosis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software